503A vs 503B Pharmacy: What the Difference Means for GLP-1
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency.
When you ask about a compounded GLP-1 medication, you may hear references to 503A or 503B pharmacies. Here is what these designations actually mean and why they matter for your medication.
If you are researching compounded semaglutide or tirzepatide, you may encounter these terms and wonder what they signify. Are they different types of pharmacies? Does one produce safer medications? Does the designation matter for your decision?
The short answer: Both are legal categories of compounders under federal law. 503A pharmacies are overseen mainly by state boards of pharmacy, and 503B outsourcing facilities mainly by the FDA[1]. They operate under different rules and have different capabilities. But neither produces FDA-approved medications, and the designation alone does not tell you whether a specific pharmacy is trustworthy or whether its products meet quality standards.
The basic distinction
503A pharmacies are traditional compounding pharmacies. They are licensed by the state, and state boards of pharmacy have primary responsibility for their day-to-day oversight[1]. Under section 503A of the Federal Food, Drug, and Cosmetic Act, they compound for an identified individual patient based on a valid prescription[3][6]. The law allows compounding before a prescription arrives only in limited quantities, based on a history of prescriptions for that patient or prescriber[6]. 503A pharmacies do not register with the FDA as outsourcing facilities and are not subject to CGMP requirements, although the FDA does conduct surveillance and for-cause inspections of them[1].
503B outsourcing facilities are a voluntary category created by the Drug Quality and Security Act of 2013[3]. An outsourcing facility compounds sterile drugs, has elected to register with the FDA, and must comply with all of section 503B[7]. Outsourcing facilities must follow current good manufacturing practice (CGMP) requirements, are inspected by the FDA on a risk-based schedule, and must report adverse events and give the FDA information about the products they compound[3][7]. They may distribute compounded drugs with a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified patient (for example, office stock)[3].
Key differences side by side
| Feature | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Primary oversight | State board of pharmacy | FDA |
| Patient-specific prescription | Required (limited advance compounding allowed) | Not required; may fill orders for office stock |
| Registered with FDA as outsourcing facility | No | Yes |
| FDA inspection | Surveillance and for-cause inspections | Risk-based schedule |
| CGMP requirements | No | Yes |
| Required to report adverse events to FDA | No | Yes |
| Products FDA-approved | No | No |
Sources: FDA[1][3][7][8]; 21 U.S.C. 353a and 353b[6].
What FDA registration means (and what it doesn’t)
This is the most commonly misunderstood point, so let’s be clear: FDA registration of a facility is not the same as FDA approval of the products it makes.
When a facility registers as a 503B outsourcing facility, it becomes subject to FDA inspection and must follow CGMP requirements[3]. This is a regulatory classification for the facility. It means the FDA has oversight authority. It does not mean the FDA has reviewed the medications produced at that facility or determined them to be safe and effective. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before they are marketed[1].
FDA approval of a drug works differently. FDA reviewers examine the company’s data and proposed labeling, and the drug is approved for sale only if that review establishes that its health benefits outweigh its known risks[4]. Neither 503A pharmacies nor 503B outsourcing facilities produce FDA-approved products, even when the facility itself is FDA-registered.
Think of it this way: A commercial kitchen that is health department-inspected is subject to oversight and quality standards. That does not mean everything produced there is approved by the health department. The inspection checks that the kitchen meets certain standards, but it does not vouch for every individual dish made there.
What 503B designation actually means for safety
Because 503B outsourcing facilities must follow CGMP requirements and are inspected by the FDA, they are held to higher quality standards than 503A pharmacies, which are not subject to CGMP[1].
Here is what that means in practice:
The FDA describes outsourcing facilities as subject to increased quality standards[1]. Outsourcing facilities report to the FDA in June and December each year which drugs they compounded in the previous six months[7], and they must report adverse events[3]. The FDA inspects them on a risk-based schedule and can take actions such as a warning letter, seizure, or injunction[2].
However, a higher standard does not equal guaranteed safety or effectiveness. The FDA’s list of registered outsourcing facilities (updated as of September 30, 2026) shows, for each facility, the date of its last inspection, whether investigators issued a Form FDA 483 listing objectionable conditions, and any action taken, and some entries show warning letters[2]. FDA inspection checks compliance with manufacturing standards. It is not a guarantee that every product is safe, and it does not mean a compounded product will work the same way as a brand-name drug.
Poor compounding practices in any setting can cause serious quality problems, such as contamination or a drug with too much or too little active ingredient[1].
What to look for when evaluating a compounding pharmacy
The 503A vs 503B designation is one data point, but it is not the only factor to consider. When evaluating a compounding pharmacy source, you can ask about:
Active state pharmacy license. This confirms the pharmacy is licensed in its state. You can verify this through the state board of pharmacy website.
PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) offers voluntary accreditation to compounding pharmacies. If a pharmacy says it is accredited, ask for the details and confirm them with the accrediting body.
Certificate of analysis. Ask whether the pharmacy can provide a COA for the batch your medication came from, showing what it was tested for (such as potency and sterility) and the results.
FDA registration and inspection history (for 503B facilities). If a facility says it is a 503B outsourcing facility, check that it appears on the FDA’s registered outsourcing facilities list, which shows its last inspection date, whether a Form 483 was issued, and any FDA action[2]. The FDA list does not include state board actions, so check with the state board of pharmacy as well[2].
Prescription required. If a source offers to ship you compounded GLP-1 medication without a valid prescription from a licensed provider, that is a red flag. GLP-1 medications require a prescription.
What to check before using compounded GLP-1 medication
Transformation Health is an independent guide. It does not prescribe, compound, sell, or ship medication, and it does not work with pharmacies.
At most telehealth programs, a licensed provider reviews your health history and decides whether a compounded GLP-1 medication is appropriate. If it is, the prescription goes to a compounding pharmacy chosen by the program. Before you choose a program, ask which pharmacy prepares the medication, whether it is a 503A pharmacy or a 503B outsourcing facility, and where it is licensed. Then check that pharmacy yourself against the points above.
The FDA notes that people who buy compounded drugs online may not know which compounder made the drug, and it encourages consumers to research an online pharmacy or telehealth service before using it[1]. For a fuller checklist, see how to choose a safe compounding pharmacy. If you are comparing telehealth programs, see how to choose a compounded GLP-1 provider.
Transformation Health does not accept payment from providers. How we make money.
The regulatory context: Why compounded GLP-1s exist
Federal law limits how compounders may copy commercially available, FDA-approved drugs. A 503A pharmacy may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available drug product, and a 503B outsourcing facility may not compound a drug that is essentially a copy of an approved drug[6]. Outsourcing facilities also may not compound from a bulk drug substance unless it appears on the 503B bulks list or the drug is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing[6]. A drug on the shortage list is treated differently: see section 503A(b)(1)(D) (21 U.S.C. 353a) and section 503B(a)(2)(A) (21 U.S.C. 353b)[6].
Compounded semaglutide and tirzepatide became widely available while those drugs were on the FDA’s drug shortage list. Both shortages have since been resolved, according to the FDA[5]:
- Tirzepatide. The FDA reissued its determination that the tirzepatide injection shortage was resolved on December 19, 2024. It said its period of enforcement discretion for 503A pharmacies ended after a court denied a preliminary injunction on March 5, 2025, and for 503B outsourcing facilities on March 19, 2025.
- Semaglutide. On February 21, 2025, the FDA determined the semaglutide injection shortage was resolved. It said its 503A period ended after an April 24, 2025 court decision (the original end date was April 22, 2025), and its 503B period ended May 22, 2025.
As of its page dated April 1, 2026, the FDA says tirzepatide and semaglutide do not currently appear on the 503B bulks list or on its drug shortage list[5]. That page also describes how the FDA intends to judge whether a 503A compounded product is essentially a copy, and it may be updated; check it for the current statement[5]. Availability of compounded GLP-1 medications depends on federal and state law and FDA action, and cannot be guaranteed.
Key takeaways
The 503A vs 503B distinction is about regulatory structure and oversight. It does not make either type’s products FDA-approved. Both types of pharmacies can produce quality compounded medications when they follow proper procedures. Both can also produce substandard medications if their practices are poor.
503B registration means federal oversight and CGMP requirements, a stricter framework than 503A pharmacies are held to[1]. But federal inspection does not guarantee safety or effectiveness, and state-level oversight does not rule out quality.
What matters most is not the designation itself, but whether the specific pharmacy follows good practices, can document its quality processes, maintains its licenses, and operates transparently. A program you are considering should be able to tell you which pharmacy it uses and what type it is.
If you want to know where a medication comes from, how it is made, or what quality documentation exists, ask the program and the pharmacy directly. Those are reasonable questions, and a program that will not answer them is a reason to keep looking.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Content current as of 09/16/2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (Accessed 2026-10-16. Supports: compounded drugs not FDA-approved and not verified for safety, effectiveness, or quality; state board primary oversight of 503A pharmacies and FDA surveillance and for-cause inspections; FDA primary oversight and risk-based inspection of outsourcing facilities; CGMP applies to outsourcing facilities, not 503A; quality risks; buying compounded drugs online.)
[2] U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” Content current as of 10/13/2026; table updated as of 9/30/2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (Accessed 2026-10-16. Supports: list of registered 503B facilities with last inspection, Form 483, and FDA action columns; possible actions include warning letter, seizure, or injunction; table excludes state board actions.)
[3] U.S. Food and Drug Administration. “Human Drug Compounding Laws.” Content current as of 12/17/2024. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws (Accessed 2026-10-16. Supports: DQSA 2013; 503A patient-specific prescriptions and exemption from CGMP; 503B voluntary category, CGMP, office-stock orders, risk-based inspection, adverse event and product reporting.)
[4] U.S. Food and Drug Administration. “Development and Approval Process: Drugs.” Content current as of 08/08/2022. https://www.fda.gov/drugs/development-approval-process-drugs (Accessed 2026-10-16. Supports: FDA review of company data and approval when benefits outweigh known risks.)
[5] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16. Supports: tirzepatide and semaglutide shortage resolution and enforcement discretion dates; not on the 503B bulks list or drug shortage list; essentially-a-copy approach.)
[6] Federal Food, Drug, and Cosmetic Act sections 503A (21 U.S.C. 353a) and 503B (21 U.S.C. 353b). https://www.law.cornell.edu/uscode/text/21/353a and https://www.law.cornell.edu/uscode/text/21/353b (Accessed 2026-10-16. Supports: 503A patient-specific prescription and limited advance compounding, essentially-copy limit, shortage provision 503A(b)(1)(D); 503B bulk drug substance limits 503B(a)(2)(A), essentially-a-copy limit 503B(a)(5).)
[7] U.S. Food and Drug Administration. “Information for Outsourcing Facilities.” Content current as of 03/29/2022. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities (Accessed 2026-10-16. Supports: definition of an outsourcing facility; CGMP; risk-based inspection; adverse event reporting; product reports in June and December.)
[8] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16. Supports: federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to FDA.)
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication, and this page does not endorse any compounding pharmacy or product. A licensed provider decides whether a prescription is appropriate. Compounded medications prepared by 503A pharmacies and 503B outsourcing facilities are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality[1]. Compounded semaglutide and tirzepatide are not the same as brand-name products and may differ in formulation, purity, and potency. Availability of compounded GLP-1 medications depends on FDA policy and applicable state and federal pharmacy compounding laws, which may change. Transformation Health does not accept payment from providers. How we make money.